Circle8 Group Inc. (CIRC)
CIRC trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1605888/000160588826000017/0001605888-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CIRC on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001605888 |
| SEC industry code | Services-Help Supply Services |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $435.9M |
| Net income | -$59.4M |
| Operating income | -$50.2M |
| Net margin | -13.6% |
| Operating margin | -11.5% |
| Revenue growth | -1.5% |
| Cash | $81K |
| Total assets | $113.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Circle8 has concluded that there is substantial doubt about its ability to continue as a going concern for at least one year from the date of issuance of its unaudited condensed consolidated financial statements." | 10-Q 2026-08-19 |
| Cash and burn | $19.3M cash; operating cash flow -$5.8M a quarter. | Report 2026-06-30 |
| Shares outstanding | 114,406,923 (2026-08-14); 58,375,488 a year earlier; 13,886,379 three years earlier. 3y figure adjusted for split (1-for-40 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-23 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-19 |
| Auditor | RBSM LLP, LAS VEGAS, Nevada, United States | PCAOB Form AP 2026-04-16 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-08-17 |
| Insider trades, 12 months | Bought $0, sold $309K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $319.8M | -$86.4M | -$3.8M | $19.3M | $568.4M | $799.9M | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | $249.9M | -$30.7M | -$9.9M | $24.1M | $513.2M | $583.0M | 10-Q 2026-06-22 |
| Q4 2025 2025-12-31 | $120.0M | -$27.1M | -$8.2M | $81K | $84.7M | $435.9M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $110.1M | -$10.8M | -$1.3M | $83K | $76.4M | $445.4M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $102.9M | -$10.7M | -$9.5M | $375K | $75.4M | $443.1M | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | $102.8M | -$10.7M | $14.6M | $1.5M | $66.9M | $444.8M | 10-Q 2026-06-22 |
| Q4 2024 2024-12-31 | $129.5M | -$68.7M | -$426K | $679K | $80.6M | $442.6M | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $107.8M | -$7.0M | -$1.3M | $1.4M | $80.8M | $429.3M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B7 | 2026-10-07 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-08-19 |
| Latest current report | 8-K | 2026-10-23 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-11-03 |
Source: SEC EDGAR submissions feed, 319 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.2% |
| 1 month | -49.0% |
| 3 months | -72.9% |
| Year to date | -86.2% |
| 1 year | -93.0% |
| From 52-week high | -95.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BNGO | Bionano Genomics Inc. | $0.9400 | -6.00% | $13.1M |
| EYPT | EyePoint Inc. | $0.3076 | +0.52% | $35.0M |
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| ASTC | Astrotech Corporation (DE) | $3.76 | -10.48% | $8.0M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier